Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents

scientific article

Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.DRUGALCDEP.2016.10.021
P932PMC publication ID6534140
P698PubMed publication ID27810652

P50authorEmily C WilliamsQ79205279
P2093author name stringJudith I Tsui
Feng Su
George N Ioannou
Kristin Berry
Pamela K Green
P2860cites workThe validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databasesQ45332145
Predictors of response of US veterans to treatment for the hepatitis C virusQ45332298
Implementation of evidence-based alcohol screening in the Veterans Health Administration.Q45332595
The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C.Q45333263
Management of hepatitis C virus infection in heavy drinkersQ45352065
The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infectionQ45358076
Alcohol use and treatment of hepatitis C virus: results of a national multicenter studyQ45416751
Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysisQ45422773
Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosisQ45756849
AUDIT-C scores as a scaled marker of mean daily drinking, alcohol use disorder severity, and probability of alcohol dependence in a U.S. general population sample of drinkers.Q48443347
FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotestQ62658359
Hepatitis C and alcoholQ80983273
The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification TestQ28282539
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002Q29619974
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care SystemQ30841159
Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient dataQ30926045
Alcohol use and hepatitis C.Q34008546
Alcohol impairs interferon signaling and enhances full cycle hepatitis C virus JFH-1 infection of human hepatocytesQ34258650
Systematic review: effect of alcohol intake on adherence to outpatient medication regimens for chronic diseasesQ34433709
Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and womenQ34520930
Quality concerns with routine alcohol screening in VA clinical settings.Q34594514
Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infectionQ34777639
Factors Underlying Quality Problems with Alcohol Screening Prompted by a Clinical Reminder in Primary Care: A Multi-site Qualitative StudyQ35876676
Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010Q36035889
The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care planQ36185899
Ethanol metabolism alters major histocompatibility complex class I-restricted antigen presentation in liver cellsQ37162792
Prevalence of clinically recognized alcohol and other substance use disorders among VA outpatients with unhealthy alcohol use identified by routine alcohol screening.Q38173126
Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans AffairsQ38323723
Local Implementation of Alcohol Screening and Brief Intervention at Five Veterans Health Administration Primary Care Clinics: Perspectives of Clinical and Administrative Staff.Q38387392
Hepatitis C and hospital outcomes in patients admitted with alcohol-related problemsQ39733097
Association of Hepatitis C Virus With Alcohol Use Among U.S. Adults: NHANES 2003-2010.Q39766673
Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013.Q40645393
Rising Mortality Associated With Hepatitis C Virus in the United States, 2003-2013.Q40769735
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United StatesQ40786866
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virusQ41701742
Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradicationQ42943658
Hepatitis C infection and alcohol use: A dangerous mix for the liver and antiviral immunityQ42999228
Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national studyQ43001380
Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United StatesQ43033283
Incidence and predictors of hepatocellular carcinoma in patients with cirrhosisQ43037842
Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study.Q43119790
Two brief alcohol-screening tests From the Alcohol Use Disorders Identification Test (AUDIT): validation in a female Veterans Affairs patient populationQ44403557
The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.Q44979610
P407language of work or nameEnglishQ1860
P921main subjecthepatitis CQ154869
Hepatitis C virusQ708693
alcohol consumptionQ2647488
P304page(s)101-109
P577publication date2016-10-22
P1433published inDrug and Alcohol DependenceQ5308875
P1476titleAlcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents
P478volume169

Reverse relations

cites work (P2860)
Q89560966Alcohol Use and Long-Term Outcomes Among U.S. Veterans Who Received Direct-Acting Antivirals for Hepatitis C Treatment
Q47554322Co-existing Hepatitis C and Alcoholic Liver Disease: A Diminishing Indication for Liver Transplantation?
Q59354016Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C
Q92464092Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct-Acting Antivirals
Q40050150HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma
Q91801771Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Q57166986Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework
Q59350262Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and Hepatitis C and/or HIV
Q59353966No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk
Q38775528Primary Care and Hepatology Provider-Perceived Barriers to and Facilitators of Hepatitis C Treatment Candidacy and Adherence
Q90307952Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users
Q54213589Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use.
Q58769427S100B and Inflammatory Cytokine Levels in Blood as Potential Markers of Blood-Brain Barrier Damage and Psychiatric Impairment in Comorbid Hepatitis C Viral Infection and Alcohol Use Disorder
Q90601704Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study)